Jim Greenwood

  • sam patrick posted an article
    New leadership named at helm of BIO see more

    The Executive Committee of the Biotechnology Innovation Organization (BIO) and its Board of Directors have announced the appointment of Dr. Michelle McMurry-Heath to lead BIO at this pivotal moment in our organization’s history, effective June 1, 2020.  

    "With her background as a scientist and physician, her health policy and experience in federal government, her leadership within industry as a champion of scientific progress, her commitment as an advocate for patients, and her gifts as a communicator, Dr. McMurry-Heath is the right person at the right time to lead us into the future," the official announcement released today stated.

    Dr. McMurry-Heath is a coalition-builder and change agent who comes to BIO from Johnson & Johnson (J&J). She served in numerous senior leadership roles at J&J since 2014, most recently serving as Vice President of External Innovation, Global Leader for Regulatory Science and Executive Director of Scientific Partnerships for JLABS @ Washington, D.C. There, she led a large global team charting the evidence generation and regulatory strategy across J&J’s medical device companies. And she worked to knock down regulatory barriers that were hindering the ability of small innovators to partner and grow.

    Prior to her work at J&J, Dr. McMurry-Heath served in scientific leadership roles at the FDA from 2010 to 2014. Her driving purpose at the FDA was to devise strategies to incorporate the patient point of view into FDA decision-making and develop new ways for patients to collaborate with innovators.

    BIO’s incoming leader is a clinician-scientist with experience working at the bench in molecular immunology. She is the first African-American to graduate from Duke’s Medical Scientist Training Program, receiving an MD/PhD in immunology along the way. While Harvard-educated, she was raised in the San Francisco Bay Area – one of the great epicenters of biotechnology.

    Throughout her impressive career, Dr. McMurry-Heath has been focused on the social impact of medicine so that more people in our society can benefit from its transformative potential. She led health and science policy on Capitol Hill for Senator Joe Lieberman, where she drafted legislation to protect the country from biological attacks, and then went on to sharpen her policy skills at the Robert Wood Foundation.

    Dr. McMurry-Heath will become just the third leader of BIO since our organization’s founding in 1993. She will succeed a towering figure in our industry, the Honorable Jim Greenwood, who for 16 years has built the most consequential biotechnology advocacy organization in the world.  Mr. Greenwood was a champion of the cause even before he was BIO's leader, reforming the FDA and fighting for broad acceptance of stem-cell science during his 12 years of principled, pragmatic leadership in the United States Congress.

    As BIO’s leader, Mr. Greenwood has brought incomparable political and policy acumen to bear on the needs of our industry. During his tenure at BIO and as the United States built an innovation ecosystem that is the envy of the world, he played a pivotal role. After he hands over the reins on June 1st to Dr. McMurry-Heath, he has committed to work with her and will stay on in a strategic advisory role. The industry and BIO are grateful for his outstanding leadership, professionalism and continued contribution.

  • sam patrick posted an article
    BIO CEO Jim Greenwood tripled organization’s size, built bridges to create innovation ecosystem see more

    The Biotechnology Innovation Organization (BIO) today announced that industry veteran Jim Greenwood will step down as President and CEO of the world’s largest biotechnology organization after the 2020 election and help transition a new leader to represent the industry globally and to defend innovation from domestic political attacks.

    “I’ve been twice blessed – to represent the American people in Congress and then to represent the extraordinary scientists and entrepreneurs of the biotechnology industry,” Jim Greenwood said. “No organization has played a more powerful role than BIO in making sure government leaders embrace thoughtful policy so the science of biotechnology can march forward. I know because I was one of those lawmakers inspired by my BIO education. Through this organization, I came to see the miracles the biotech industry makes possible.”

    “Jim’s pragmatic, ethical, patient-first leadership of BIO for more than 14 years has allowed the United States to create a pro-innovation public policy environment that’s the envy of the world, and I say that as someone who has led biopharmaceutical companies in three countries,” said BIO Chairman Jeremy Levin, CEO of Ovid Therapeutics, a biotech company working on cures for rare neurological disorders. “All of us at BIO will continue to depend on his thoughtful stewardship for the next 15 months as we fight short-sighted attempts to drain capital from our sector and curtail the intellectual property rights of innovators.”

    Read the complete story here.

  • sam patrick posted an article
    BIO global CEO Jim Greenwood, Over 50 National Speakers to Present at SCBIO 2018 see more

    Conference registrations soar with sell-out expected; CEOs and top industry leaders head to Charleston for strategic partnership development, industry insights

     

    SOUTH CAROLINA – September 26, 2018BIO global CEO Jim Greenwood will join more than 50 additional national speakers at SCBIO 2018 – the annual conference bringing top leaders and executives from life sciences organizations across the state and nation to Charleston, South Carolina October 23-25.

    Mr. Greenwood will address the gathering with a keynote presentation entitled “Global Perspectives for Life Sciences – Compelling Opportunity for South Carolina” the morning of the conference opening on October 24.  His presentation will be bracketed by two high-powered panel discussions – a feature panel comprised of top pharmaceutical executives entitled “Pharma’s Future in the Palmetto State and Beyond,” and followed by the Southeast US Economic Development Luncheon featuring an address by Secretary of Commerce Bobby Hitt.  The luncheon will be capped by a panel featuring life sciences economic development CEOs from across the Southeastern region.  Conference Chair and Womble Bond Dickinson partner Stephanie Yarbrough will moderate the luncheon panel.

    Scores of top industry chief executives, leaders in government and higher education, biotechnology and pharma executives, clinicians and researchers, and industry supporters from across America have already registered to attend SCBIO 2018 at Charleston’s Gaillard Auditorium, with registration already doubling the pace of 2017.  Among committed speakers and panelists are DePuy Synthes Global Orthopedic Leader I.V. Hall, Nephron Pharmaceuticals CEO Lou Kennedy, J.P. Morgan Executive Director of Healthcare Investment Banking Bell Zhong, MUSC President David Cole, USC President Harris Pastides, Siemens Healthineers North Americas President Dave Pacitti, and numerous others.

    Themed “Connect.  Collaborate.  Advance!” the 2+ day conference draws attendees from across America for networking, innovation updates, opportunity discovery, partnership making and strategic discussion.  Committed attendees include officials across a broad spectrum of life sciences industries including medical devices, bio manufacturing, drug discovery, pharmaceuticals, diagnostics and testing, digital health and health IT, bio ag  and more.  Space is limited and advance registration is still available at https://www.scbio.org/events/scbio-annual-conference.

    SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has an $11.4 billion economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products. 

    SCBIO 2018 kicks off Tuesday evening October 23 with an Opening Reception for conference registrants, speakers and sponsors at The Dewberry Hotel, presented by Explore Charleston and The Dewberry.  Wednesday will feature a complete day of sessions beginning at breakfast and continuing through a gala evening reception presented by Womble Bond Dickinson.  The conference will wrap up Thursday at lunchtime. 

    “The life sciences industry is a major driver of South Carolina’s economy, and this conference is testament to the industry’s growing impact, reach and rapidly rising economic significance in our state and region,” noted SCBIO President and CEO Sam Konduros. “Already accounting for thousands of highly-skilled jobs in the Palmetto State, this sector has tremendous growth potential, and we’re excited to showcase the top companies, research universities and leaders from across our state and country at SCBIO 2018.” 

    Among leading biotech and med-tech industry brands participating in the conference are Nephron Pharmaceutical, BIO, Johnson & Johnson, AVX, PhRMA, DePuy Synthes, Medpoint, AdvaMed, Poly-Med, VWR, Ritedose Corporation, Rhythmlink, SoftBox Systems, ZEUS, Patheon Thermo Fisher and more.  All of South Carolina’s research universities – MUSC, Clemson and the University of South Carolina – are represented, as are major healthcare systems, and economic development entities including the South Carolina Department of Commerce, SCRA, the Upstate SC Alliance, the Charleston Regional Development Alliance, Central Carolina Alliance and SiMT.

    As the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations – SCBIO members include hundreds of academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world.

  • sam patrick posted an article
    Top speakers and brands are committing to attend SCBIO 2017 in Charleston this October; have you sig see more

    BIO global CEO Jim Greenwood will join South Carolina Governor Henry McMaster as featured luncheon speakers on the first full day of SCBIO 2017 – the annual conference bringing top leaders and executives from organizations across the life sciences industry to Charleston, South Carolina October 24–26.

    Mr. Greenwood will be addressing the gathering with a keynote presentation entitled “Global Trends for the Life Sciences Industry – and Implications for South Carolina” at lunch on October 25.  South Carolina Governor Henry McMaster will follow with a presentation entitled “Life Sciences Powered by Public/Private Partnership – A Strategic View from the Statehouse.”

    Dozens of top industry chief executives, leaders in government and higher education, biotechnology and pharma executives, and industry supporters from across America have already committed to attend SCBIO 2017 at Charleston’s Gaillard Auditorium, organizers confirmed today.  Among the committed speakers and panelists are Nephron Pharmaceuticals CEO Lou Kennedy, MUSC President David Cole, Clemson University President Jim Clements, USC President Harris Pastides, Medpoint CEO Chuck Crumpton, Belimed CEO Joseph McDonald, AVX Health Division executive Robert Fairey and numerous others.

    Themed “Building the Business of Life SCiences in SC”, the 2+ day conference draws attendees from across America for networking, innovation updates, opportunity discovery, partnership making and strategic discussion.  Committed attendees include officials across a broad spectrum of life sciences industries including medical devices, bio manufacturing, drug discovery, pharmaceuticals, diagnostics and testing, digital health and health IT, bio ag  and more.  While space is limited and advance registration is required, interested attendees can still register at http://scbio2017.eventbrite.com.

    SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has an $11.4 billion economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products. 

    SCBIO 2017 kicks off Tuesday evening with a Welcome Reception for conference registrants, speakers and sponsors on the rooftop terrace of the Grand Bohemian Hotel.  Wednesday will feature a full day of sessions beginning at breakfast with a greeting by Charleston Mayor John Tecklenburg and continuing through an evening reception.  The conference will wrap up Thursday at lunchtime. 

    “The life sciences industry has become a major driver of South Carolina’s economy,” noted South Carolina Secretary of Commerce Bobby Hitt recently. “Already accounting for thousands of highly-skilled jobs in the Palmetto State, we know that this sector has tremendous growth potential, and we’re excited to be partnering with SCBIO to help life sciences continue to advance in South Carolina.”  SC Commerce is a Founding Partner of SCBIO and of the Conference.

    Among the leading biotech industry brands participating in the conference are Nephron Pharmaceutical, BIO, Johnson & Johnson, AVX, PhRMA, Medpoint, AdvaMed, Poly-Med, VWR, Ritedose Corporation, Rhythmlink, Softbox, NCGS and SEMDA.  All of South Carolina’s research universities – MUSC, Clemson and the University of South Carolina – are attending, as is Greenville Health System and economic development entities including SCRA, the Upstate SC Alliance, the Charleston Regional Development Alliance and SiMT.

    As the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations – SCBIO members include hundreds of academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world.

    For additional information on SCBIO, visit www.SCBIO.org.  To register for SCBIO 2017, visit http://scbio2017.eventbrite.com